Effect of reverse transcriptase inhibitors and mutations on the low-cost cavidi reverse transcriptase viral load assay

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 4, 2009, Pages 527-529

  Van Rooijen, Lisette B ^a,b   Greengrass, Vicki ^a   Morris, Lisa M ^a   Plate, Megan M ^a   Gouillou, Maelenn ^a   Tachedjian, Gilda ^a,c,d   Sluis Cremer, Nicolas ^e   Hearps, Anna C ^a   Crowe, Suzanne M ^a,e  

^a BURNET INSTITUTE   (Australia)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MONASH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ASSAY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

HIV; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 74049164757     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b9e726     Document Type: Letter

References (12)

1. Seyoum E, Wolday D, Girma M, et al. Reverse transcriptase activity for quantitation of HIV-1 subtype C in plasma: relation to RNA copy number and CD4 T-cell count. J Med Virol. 2006;78:161-168.
2. Crowe S, Turnbull S, Oelrichs R, et al. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis. 2003;37(Suppl 1):S25-S35.
3. Fiscus SA, Cheng B, Crowe SM, et al. HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006;3:e417.
4. Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab. 2007;53:135-148.
5. Malmsten A, Shao XW, Sjodahl S, et al. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol. 2005;76:291-296.
6. Greengrass VL, Turnbull SP, Hocking J, et al. Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Curr HIV Res. 2005;3:183-190.
7. Jennings C, Fiscus SA, Crowe SM, et al. Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol. 2005;43:5950-5956.
8. Deval J, Navarro JM, Selmi B, et al. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem. 2004;279: 25489-25496.
9. Deval J, White KL, Miller MD, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem. 2004;279:509-516.
10. Parikh UM, Zelina S, Sluis-Cremer N, et al. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS. 2007;21:1405-1414.
11. Sivapalasingam S, Essajee S, Nyambi PN, et al. Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J Clin Microbiol. 2005;43: 3793-3796.
12. Steegen K, Luchters S, De Cabooter N, et al. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J Virol Methods. 2007.